Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Key PointsRoche's leading weight loss and diabetes candidate has posted excellent Phase 2 clinical trial results.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market. fool.com
- Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market. nasdaq.com
